Figure 4.

Apical sodium bile acid (BA) transporter (ASBT) ASBT Vivo-Morpholino (VM) treatment alters enterohepatic and decreases cholehepatic total bile acid (TBA) levels. Multidrug-resistant 2 knockout (Mdr2^−/−) Control mice had increased TBA levels in serum (A), liver (B), feces (C) compared with all wild-type (WT) mice. ASBT VM treatment reduced serum (A) and feces (C) TBA in Mdr2^−/− mice and increased serum (A) TBA in WT mice. Intestinal TBA levels were unchanged between WT and Mdr2^−/− mice treated with Control or ASBT VM (D). Isolated hepatocyte supernatant (E) and cholangiocyte supernatant (F) TBA content increased in Mdr2^−/− Control mice compared with WT mice, and ASBT VM treatment reduced TBA content in both hepatocyte and cholangiocyte supernatants [collected from isolated cells pooled from 7 to 10 mice per group and incubated in HEPES-buffered saline (HBS) with 0.1 M CaCl₂ in a 37°C shaking water bath for 4 h]. Data are presented as mean ± SD of 4–7 experiments from 7–10 mice per group. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.